MOTS-c vs Tesamorelin

Written by the Pure Peptides editorial team

Reviewed by Dr. Martina Rossi, PhD

Scientific Contributor and Reviewer · Reviewed

Published · Updated · 8 references

MOTS-c and Tesamorelin are different molecules: MOTS-c is a 16-residue peptide encoded within a ribosomal RNA gene, and Tesamorelin is a 44-residue analog of human growth hormone-releasing hormone.

vs
Tesamorelin

Tesamorelin

View Tesamorelin

Structure at a glance

Each chain as stored in the product database, one box per residue. The two are drawn separately; no alignment between them is implied.

MOTS-c · 16 residues

Tesamorelin · 44 residues

Hex: N-terminal trans-3-hexenoyl group. NH2: C-terminal amide. Letters are one-letter amino acid codes.

Chain length
MOTS-c16 residues
Tesamorelin44 residues
Molecular weight
MOTS-c2,174.62 g/mol
Tesamorelin5,135.86 g/mol

Drawn from the product database. Each measure's bars share one scale.

MOTS-c vs Tesamorelin, compared
What it isA 16-residue peptide encoded by a short open reading frame within the mitochondrial 12S rRNA gene.[1] Ends in a free C-terminal acid.A 44-residue peptide: an analog of human growth hormone-releasing hormone with an N-terminal trans-3-hexenoyl group.
How they relateDifferent molecules. MOTS-c is encoded by a short open reading frame within the mitochondrial 12S rRNA gene.[1] Tesamorelin is an analog of the full 44-residue human growth hormone-releasing hormone.
CAS number1627580-64-6218949-48-5
Molecular formulaC101H152N28O22S2C221H366N72O67S
Molecular weight2,174.62 g/mol5,135.86 g/mol
SequenceMRWQEMGYIFYPRKLRtrans-3-hexenoyl-YADAIFTNSYRKVLGQLSARKLLQDIMSRQQGESNQERGARARL-NH2
Evidence baseAnimal and cell studies. No completed controlled study testing MOTS-c in people has published results. Human studies in the literature reviewed for it measured the body's own MOTS-c.Human studies, which supported an approval for one indication. A pooled analysis of two phase 3 trials covered 806 randomized participants.[2] Their primary endpoints were imaging surrogates. The trial papers were manufacturer-sponsored.
Regulatory statusMOTS-c is not approved for human therapeutic use, and Drugs@FDA holds no approved application for it.[3]The FDA approved tesamorelin acetate in 2010 for one therapeutic indication.[4][5] That approval is current.
Compared head-to-head?No direct comparison found in PubMed (searched October 2026).[6]
Handling differenceNeither contains a cysteine. MOTS-c has three oxidation-prone residues: two methionines and a tryptophan. Tesamorelin has one methionine, which oxidizes on air exposure.

How MOTS-c and Tesamorelin differ

MOTS-c and Tesamorelin are different molecules. MOTS-c is a 16-residue peptide encoded by a short open reading frame within the mitochondrial 12S rRNA (ribosomal RNA) gene.[1] Its chain has a free N-terminal amine and a free C-terminal acid. MOTS-c made by solid-phase synthesis is usually supplied as a salt. Tesamorelin is a synthetic analog of the full 44-residue human growth hormone-releasing hormone (GHRH). Its chain carries a trans-3-hexenoyl group on the N-terminus and is amidated at the C-terminus.

No completed controlled study testing MOTS-c in people has published results. In the literature reviewed for MOTS-c, the human studies measured the body's own MOTS-c. The findings of the 2015 paper that first described MOTS-c are animal and cell findings, and none of them has been shown in humans.[1] The literature reviewed for MOTS-c reports no human safety data.

A pooled analysis of Tesamorelin's two phase 3 trials covered 806 randomized participants.[2] In the literature reviewed for Tesamorelin, those trials used imaging surrogates as primary endpoints, not clinical outcomes. The two trial papers and the pooled analysis were manufacturer-sponsored, with sponsor-affiliated co-authors. In the first of the two randomized placebo-controlled phase 3 trials, withdrawal because of an adverse event was higher on Tesamorelin than on placebo.[7]

MOTS-c is not approved for human therapeutic use, and Drugs@FDA holds no approved application for it.[3] The FDA approved tesamorelin acetate in 2010 for one therapeutic indication.[4][5] That approval is current, and it belongs to tesamorelin acetate and to that one indication. Tesamorelin acetate is the active ingredient of a prescription medicine sold under another name. The material supplied here is a research-grade preparation, is not that medicine, and holds no marketing authorization. That medicine's label lists glucose intolerance or new diabetes among its warnings; HbA1c reached 6.5% or above in 5% of participants on the drug against 1% on placebo.[8]

MOTS-c carries two methionines and a tryptophan, three residues that can each take up oxygen when exposed to air, light or trace metals. A glutamine gives it a second, slower route, deamidation in solution. Tesamorelin contains a single methionine, which oxidizes to a sulfoxide on air exposure. Its sequence includes asparagine and glutamine, which both deamidate. Neither contains a cysteine, so neither can form a disulfide. Tesamorelin may also aggregate on repeated freezing and thawing. In both, basic side chains bring a substantial counter-ion load.

Have MOTS-c and Tesamorelin been compared directly?

No direct comparison of MOTS-c with Tesamorelin was found in a PubMed search run in October 2026.[6] That search covers PubMed only.

Read more on each compound

Frequently Asked Questions

Is MOTS-c the same as Tesamorelin?+

MOTS-c and Tesamorelin are different molecules: MOTS-c is a 16-residue peptide encoded within a ribosomal RNA gene, and Tesamorelin is a 44-residue analog of human growth hormone-releasing hormone. Tesamorelin carries a trans-3-hexenoyl group on its N-terminus and is amidated at its C-terminus. MOTS-c has a free N-terminal amine and a free C-terminal acid.

Is MOTS-c or Tesamorelin approved?+

MOTS-c is not approved for human therapeutic use; the FDA approved tesamorelin acetate in 2010 for one therapeutic indication. Tesamorelin acetate is the active ingredient of a prescription medicine sold under another name. The material supplied here is a research-grade preparation, is not that medicine, and holds no marketing authorization.

References

  1. 1
    Lee C, et al. 2015. PMID 25738459.
  2. 2
    Pooled analysis of two phase 3 trials, 2010. PMID 20554713.
  3. 3
    US Food and Drug Administration. openFDA drug/label and drug/drugsfda endpoints, snapshot last updated 2026-08-26. Field-qualified substance-name query returned no record for MOTS-c.
  4. 4
    US Food and Drug Administration, Center for Drug Evaluation and Research. Approval letter for tesamorelin, 10 November 2010 (Reference ID 2863003).
  5. 5
    US Food and Drug Administration, Drugs@FDA. Approval record whose active ingredient is tesamorelin acetate; marketing status Prescription. Retrieved via api.fda.gov/drug/drugsfda.json on products.active_ingredients.name "TESAMORELIN ACETATE", 3 October 2026.
  6. 6

    PubMed search, 3 October 2026 (records to 2 October 2026)

    1 record; none was a direct comparison of the two compounds.

    Exact query (NCBI E-utilities): ("MOTS-c"[tiab] OR "MOTSc"[tiab] OR "MOTS c"[tiab]) AND ("tesamorelin"[tiab]) AND ("1800/01/01"[edat] : "2026/10/02"[edat])

    View this search on PubMed
  7. 7
    Phase 3 trial report, 2007. PMID 18057338.
  8. 8
    US Food and Drug Administration. Approved prescribing information for tesamorelin acetate; label version 29 July 2026. Retrieved via openFDA drug/label.
Dr. Martina Rossi, PhD

Reviewed for scientific accuracy

Dr. Martina Rossi, PhD

PhD, Université Grenoble Alpes · Scientific Contributor and Reviewer

Dr. Rossi's doctoral research at Université Grenoble Alpes examined the vascular functions of bone morphogenetic proteins. Her peer-reviewed work spans cell and molecular biology, vascular biology, and gene therapy, in journals including Cardiovascular Research, Scientific Reports, and Brain Sciences. She reviews Pure Peptides' product, reference, and research pages for scientific accuracy against the sources they cite.

Reviewed ORCIDGoogle ScholarTeam profile →
Comparison

AOD-9604 vs Tesamorelin

AOD-9604 is a modified 16-residue peptide from the C-terminal end of human growth hormone; Tesamorelin is a 44-residue analog of human GHRH.

Read Comparison
Comparison

CJC-1295 (No DAC) vs Tesamorelin

CJC-1295 (No DAC) carries four substitutions in human GHRH's first 29 residues; Tesamorelin is an analog of the full 44-residue hormone.

Read Comparison
Comparison

HGH Fragment 176-191 vs Tesamorelin

HGH Fragment 176-191 is a 16-residue fragment of human growth hormone; Tesamorelin is a 44-residue analog of human GHRH.

Read Comparison